Halberd's method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains.
JACKSON CENTER, PA / ACCESSWIRE / December 6, 2022 / Halberd Corporation (OTC PINK:HALB) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication technology which successfully eradicated numerous Gram-Negative bacteria whose results were reported in an October 18, 2022 press release. Gram-negative bacteria (GNB) are characterized by their high resistance to antibiotics.[1]
The CDC provides various strains of antibiotic resistant bacteria to research organizations to encourage development of methods and means of overcoming/neutralizing the bacteria's resistance to known antibiotics or destroying these bacteria without harming the patient.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Our results to date on E. coli, Salmonella and Shigella have been very encouraging and we are excited to commence testing of our patent-pending methodology on these antibiotic resistant strains from the CDC."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "The importance of the fact that the CDC supplied this material to Halberd Corporation cannot be over-emphasized. Halberd's patented technology could be of intense interest to the government, particularly the military, because of our ability to potentially counteract bio-weapons. We regard this responsibility as important to the potential safety and security of the country and to the interests of the company as well."
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three granted patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of innovative, forward thinking development partners.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
[1]https://pubmed.ncbi.nlm.nih.gov/30855801/
SOURCE: Halberd Corporation
View source version on accesswire.com:https://www.accesswire.com/730331/Halberd-Receives-Several-Strains-of-Antibiotic-Resistant-Bacteria-from-CDC-to-Test-Laser-Eradication
